Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Receives Consensus Rating of “Moderate Buy” from Analysts

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) has earned a consensus recommendation of “Moderate Buy” from the six brokerages that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $55.80.

Several equities research analysts recently commented on PTHS shares. Roth Mkm cut their price target on shares of Pelthos Therapeutics from $57.00 to $55.00 and set a “buy” rating for the company in a report on Thursday, February 26th. HC Wainwright restated a “buy” rating and issued a $60.00 price target on shares of Pelthos Therapeutics in a research report on Thursday, March 19th. Zacks Research upgraded shares of Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 24th. Piper Sandler started coverage on Pelthos Therapeutics in a research report on Friday, February 27th. They issued an “overweight” rating and a $48.00 target price on the stock. Finally, Cantor Fitzgerald started coverage on shares of Pelthos Therapeutics in a research note on Wednesday, April 1st. They issued an “overweight” rating and a $50.00 price target on the stock.

Pelthos Therapeutics Stock Up 0.4%

NYSEAMERICAN:PTHS opened at $27.11 on Thursday. The company has a debt-to-equity ratio of 1.41, a current ratio of 2.79 and a quick ratio of 1.86. Pelthos Therapeutics has a 52 week low of $9.00 and a 52 week high of $54.29. The company’s 50-day simple moving average is $23.77. The firm has a market cap of $94.34 million, a PE ratio of -1.31 and a beta of 3.29.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($3.09) earnings per share (EPS) for the quarter. The business had revenue of $10.91 million during the quarter. Sell-side analysts expect that Pelthos Therapeutics will post -11.7 earnings per share for the current fiscal year.

Institutional Trading of Pelthos Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of PTHS. Knott David M Jr increased its stake in Pelthos Therapeutics by 9.3% during the 1st quarter. Knott David M Jr now owns 21,073 shares of the company’s stock worth $443,000 after buying an additional 1,792 shares during the period. Geode Capital Management LLC lifted its holdings in Pelthos Therapeutics by 31.9% during the 4th quarter. Geode Capital Management LLC now owns 13,625 shares of the company’s stock worth $422,000 after buying an additional 3,295 shares during the last quarter. Persistent Asset Partners Ltd raised its holdings in Pelthos Therapeutics by 150.0% during the fourth quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company’s stock worth $186,000 after purchasing an additional 3,604 shares in the last quarter. Pale Fire Capital SE lifted its position in Pelthos Therapeutics by 59.5% in the first quarter. Pale Fire Capital SE now owns 12,919 shares of the company’s stock valued at $271,000 after acquiring an additional 4,819 shares during the last quarter. Finally, Millennium Management LLC purchased a new stake in shares of Pelthos Therapeutics in the 4th quarter valued at about $343,000. 77.96% of the stock is currently owned by hedge funds and other institutional investors.

About Pelthos Therapeutics

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).